XML 63 R38.htm IDEA: XBRL DOCUMENT
v3.25.4

LICENSE, COLLABORATION AND OTHER REVENUE (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Revenues Recognized from License, Collaboration and Other Significant Agreements | The Company recognized the following revenues from its license, collaboration and other revenue agreements (in thousands):
|  |  |  | Years Ended December 31,
Entity |  | Description |  | 2025 |  | 2024 |  | 2023
Medice |  | License and Product Supply of Vafseo in EU |  | $ | 411 |  |  | $ | 22 |  |  | $ | 10,968 |
TPC, formerly known as Mitsubishi Tanabe Pharma |  | License and Product Supply of Vafseo in Japan |  | 2,794 |  |  | 2,612 |  |  | 5,735 |
JT and Torii |  | License and royalties related to the sale of Riona in Japan |  | 5,659 |  |  | 5,366 |  |  | 5,394 |
Otsuka |  | Terminated U.S. and International Agreements |  | — |  |  | — |  |  | 2,225 |
Total License, Collaboration and Other Revenue |  | $ | 8,864 |  |  | $ | 8,000 |  |  | $ | 24,322 |
Schedule of Changes in Contract Assets and Liabilities | The following table presents changes in the Company’s contract assets and liabilities related to the Company's sales to its AG Distributor (in thousands):
|  | Year Ended December 31, 2025
|  | Balance at Beginning of Period |  | Additions |  | Deductions |  | Balance at End of Period
Contract assets: |  |  |  |  |  |  |  |
Accounts receivable |  | $ | — |  |  | $ | 12,006 |  |  | $ | (11,812) |  |  | $ | 194 |
Contract liabilities: |  |  |  |  |  |  |  |
Deferred revenue |  | $ | — |  |  | $ | 10,675 |  |  | $ | (7,994) |  |  | $ | 2,681 |
The following table presents changes in the Company’s contract assets and liabilities related to license, collaboration and other revenue agreements (in thousands):
| Year Ended December 31, 2025
| Balance at Beginning of Period |  | Additions |  | Deductions |  | Balance at End of Period
Contract assets: |  |  |  |  |  |  |
Accounts receivable(1) | $ | 2,010 |  |  | $ | 8,894 |  |  | $ | (8,513) |  |  | $ | 2,391 |
Contract liability: |  |  |  |  |  |  |
Deferred revenue | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
| Year Ended December 31, 2024
| Balance at Beginning of Period |  | Additions |  | Deductions |  | Balance at End of Period
Contract assets: |  |  |  |  |  |  |
Accounts receivable(1) | $ | 3,333 |  |  | $ | 8,562 |  |  | $ | (9,885) |  |  | $ | 2,010 |
Contract liabilities: |  |  |  |  |  |  |
Deferred revenue (long-term)(2) | $ | 43,296 |  |  | $ | — |  |  | $ | (43,296) |  |  | $ | — |
(1)Excludes accounts receivable from product sales of Auryxia and Vafseo which are included in the accompanying consolidated balance sheets as of December 31, 2025 and 2024. (2)See Note 8, Liability Related to Settlement Royalties, Working Capital Fund Liability and Liability Related to Sale of Future Royalties, for further information.
Schedule of Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities | During the years ended December 31, 2025, 2024 and 2023, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands):
|  | Years Ended December 31,
Revenue Recognized in the Period from: |  | 2025 |  | 2024 |  | 2023
Deferred revenue - beginning of the period |  | $ | — |  |  | $ | — |  |  | $ | 3,738 |

X
- Definition Collaborative arrangement revenue recognition. + References No definition available. + Details
Name: | akba_CollaborativeArrangementRevenueRecognitionTableTextBlock
Namespace Prefix: | akba_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of revenue recognized resulting from changes in contract asset and contract liability. + References No definition available. + Details
Name: | akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock
Namespace Prefix: | akba_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration